Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 20/20 | 0.98 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.98 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.98 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.98 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.98 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.98 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.98 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.98 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.98 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.98 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.62 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ricolinostat SCHEMBL574580 | 0.99 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL28085707 | 0.91 | HDAC6 (0.84) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL21943234 | 0.90 | HDAC6 (0.83) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL2226158 | 0.90 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL18347205 | 0.90 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| Citarinostat SCHEMBL2225863 | 0.90 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| Citarinostat SCHEMBL29882816 | 0.90 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL26079021 | 0.89 | HDAC6 (0.79) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL2225424 | 0.89 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL2226917 | 0.88 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11357776-B2 | Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof | ACETYLON PHARMACEUTICALS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20200046698-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND AN AURORA KINASE INHIBITOR AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS, INC. | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200046698-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND AN AURORA KINASE INHIBITOR AND METHODS OF USE THEREOF | HDAC1, HDAC3, HDAC8 | HDAC6 4/4885HDAC1 1/4885HDAC3 2/4885 |
| US-11357776-B2 | Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof | HDAC1, HDAC3, HDAC8 | HDAC6 4/4885HDAC1 1/4885HDAC3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.